Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Shares Outstanding (Weighted Average) (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $8470.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Shares Outstanding (Weighted Average) rose 10.0% year-over-year to $8470.0, compared with a TTM value of $8470.0 through Mar 2025, up 10.0%, and an annual FY2023 reading of $114.2 million, up 39.51% over the prior year.
  • Shares Outstanding (Weighted Average) was $8470.0 for Q1 2025 at Karyopharm Therapeutics, down from $118.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $118.2 million in Q2 2024 and bottomed at $7700.0 in Q1 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $79.4 million, with a median of $78.6 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 110088.24% in 2021, then tumbled 99.99% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $75.2 million in 2021, then rose by 8.84% to $81.9 million in 2022, then surged by 39.51% to $114.2 million in 2023, then increased by 3.52% to $118.2 million in 2024, then plummeted by 99.99% to $8470.0 in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for KPTI at $8470.0 in Q1 2025, $118.2 million in Q2 2024, and $7700.0 in Q1 2024.